Oncology
🇪🇺 EMA Page 4EMA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Global oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Showing 37–48 of 94 articles
Telix Pharmaceuticals' TLX101-Px (Pixlumi) Brain Cancer Imaging Drug Accepted for European Review
Antibody-Drug Conjugates in Breast Cancer: Enhertu vs. Trodelvy in EU Market
EMA Conditional Marketing Authorization: Linvoseltamab for RRMM in EU
Bispecific Antibody Approvals in EU: Teclistamab & Elranatamab Review
EMA Conditional Approval Pathway: Insights from Repotrectinib Oncology Approval
European Commission Approves POHERDY, First Pertuzumab Biosimilar in Europe by Henlius and Organon
PureTech Reports Positive LYT-200 Clinical Results for Myeloid Malignancies in 2025 Annual Results
Henlius and Organon's POHERDY Becomes First Pertuzumab Biosimilar Approved in Europe
European Biomarker-Driven Trials: EMA Regulatory Framework & Success Rates
Real-World Evidence Oncology Drugs: EMA vs MHRA Regulatory Approaches
European Pediatric Investigation Plans: Accelerating Oncology Drug Development Timelines
Novel Immunotherapies Advanced Melanoma: EMA Approval & Phase 3 Insights